Late-phase trial failure for GSK, Prosensa muscular dystrophy drug

09/23/2013 | PharmaTimes (U.K.)

A Phase III trial for drisapersen, a drug by GlaxoSmithKline and Prosensa for treating Duchenne muscular dystrophy, failed to meet primary goals three months after receiving breakthrough therapy designation from the U.S. FDA. The trial among 186 boys suffering from the disease failed to demonstrate significant improvement in walking distance or motor function, compared with a placebo. DMD affects one in 3,500 live male births.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN